L-carnitine added to standard treatment for adults with rheumatoid arthritis
Tests L-carnitine added to usual drugs in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: L-carnitine Supplementation in Rheumatoid Arthritis Patients
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06753565, who can take part
Where in Egypt
- Demerdash hospitalCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- German University in Cairo
- Trial code
- NCT06753565
- Record updated
- 7 January 2025
- Original description
This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.Read full original descriptionShow less
Effect of L-carnitine Supplementation on Disease Activity in Rheumatoid Arthritis Patients
This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.
Inclusion: age between 18-60 years old; diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months; enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study; active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2); patient or legal representative should sign informed consent.
Exclusion: Patients with any active infection or concurrent malignancy; patients currently taking drugs that could interact with carnitine like: warfarin; patients with uncontrolled medical conditions or other rheumatic diseases; patients with liver dysfunction (>1.5x the upper limit of normal value for ALT \& AST); Patients with kidney dysfunction (serum creatinine more than 1.2 mg/dl); pregnant or lactating female.